5-Hydroxytriptamine and Skeleton Influence Clinical Study

Albulescu, Dana Maria; Cârșote, Mara; Ionovici, Nina; Ghemigian, Adina; Popescu, M; Ţuculină, Mihaela Jana; Dascălu, Ionela Teodora; Preda, Smaranda Adelina; Ţîrcă, Tiberiu; Petrescu, Stelian-Mihai-Sever; Bătăiosu, Marilena; Bechir, Edwin Sever

doi:10.37358/rc.18.9.6549

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many bone-derived factors as well as bone targeting molecules, biomarkers and hormones like prolactin, serotonin, sclerostin, etc. are probably related to skeleton profile and most of them are not tested in daily practice in order to evaluate to fracture risk reduction under specific bone forming medication [17][18][19].…”

Section: Resultsmentioning

confidence: 99%

Clinical Data on Transitory Teriparatide-related Hypercalcemia in Daily Practice Treatment for Severe Menopausal Osteoporosis

Bechir¹,

Ţuculină²,

Cârșote³

et al. 2019

Rev. Chim.

Self Cite

View full text Add to dashboard Cite

Teriparatide (TPT) (C181H291N55O51S2) represents a recombinant molecule acting as human osteoanabolic agent. Transitory hypercalcemia (TH) has been reported in osteoporotic patients treated with daily TPT. Our purpose is to analyze the biochemical features as well as clinical risk factors for fractures in patients with severe osteoporosis treated with TPT who developed TH during first 12 months. This is an observational real-life study. In patients with TH biochemical blood markers like osteocalcin, CrossLaps and P1NP assessed at one year have statistically significant higher values than in subjects associating serum calcium within normal limits under the drug.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical Data on Transitory Teriparatide-related Hypercalcemia in Daily Practice Treatment for Severe Menopausal Osteoporosis

Bechir¹,

Ţuculină²,

Cârșote³

et al. 2019

Rev. Chim.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thus include: Chronic inflammation [for example, higher levels of pro-inflammatory cytokine tumor necrosis factor (TNF) have been reported], high cortisol values, anomalies of leptin (such as low circulating levels or high soluble leptin receptor levels) and of adiponectin, impaired bone-gut-fat communication and abnormal variations of bone turnover markers (22,23). Constant exposure to high oxidative status and dysregulation of the gut microbiota represent other contributors to skeleton status damage (24,25).…”

Section: Bone Statusmentioning

confidence: 99%

Anorexia nervosa: COVID‑19 pandemic period (Review)

et al. 2021

Self Cite

View full text Add to dashboard Cite

Anorexia nervosa is an eating disorder characterized by restrictive eating and an intense fear of gaining weight. It is a disease with an increasing incidence during the last few decades, and represents a complex psychiatric condition which includes secondary amenorrhea, nutritional and metabolic damage, and impaired endocrine panel up to bone loss as well as cardiac, gastrointestinal and hematological complications. This is a narrative review which includes an update on this eating disorder from the perspective of an endocrine panel of anomalies, especially of the skeleton, considering the pressure of the recent global COVID-19 pandemic changes. Practically affecting every organ, anorexia nervosa needs to be taken into consideration during the pandemic period because of the higher risk of relapse due to new living conditions, social distancing, self-isolation, changes in food access, more intense use of social media platforms, disruption of daily habits, and more difficult access to healthcare practitioners. The lack of physical activity in addition to vitamin D deficiency related to low sun exposure or to the use of facial masks may also be connected to further bone damage related to this disease.

show abstract

“…Increased blood levels of somatostatin are found in different amounts depending on tumour production (30). Neuroendocrine markers that are less specific such as chromogranin A, neurron specific enolase, and 5-hydroxytryptamine might help the diagnosis and follow-up (30,31,34). Imaging techniques are widely variable such as ultrasound, computed tomography, magnetic resonance imagery, positronic emission tomography (PET), and somatostatin receptor imaging (SRI) such as octreoscan/ 68 Ga (Gallium)-DOTATATE (30,35).…”

Section: Somatostatin Secreting Tumoursmentioning

confidence: 99%

Somatostatinoma: Beyond neurofibromatosis type 1 (Review)

Şandru

Cârșote

Valea³

et al. 2020

Exp Ther Med

Self Cite

View full text Add to dashboard Cite

Somatostatinoma is a tumour mainly originating from pancreas or duodenum; overall with an incidence of 1/40 million persons. We introduce a narrative review of literature of somatostatinoma including the relationship with neurofibromatosis type 1. Clinical presentation includes: Diabetes mellitus, cholelithiasis, steatorrhea, abdominal pain, and obstructive jaundice while papillary tumour may cause acute pancreatitis. The neoplasia may develop completely asymptomatic or it is detected as an incidental finding during an imaging or a surgical procedure. It may be sporadic or associated to genetic backgrounds especially for duodenal localisation as neurofibromatosis type 1 (NF1 gene with malfunction of RAS/MAPK pathway) or Pacak-Zhuang syndrome (EPAS1 gene encoding HIF). Surgery represents the central approach if feasible but the prognostic depends on location, and grading as indicated by WHO 2017 classification of neuroendocrine tumours. Previously known as Von Recklinghausen disease, neurofibromatosis type 1, the most frequent neurocutaneous syndrome, is an autosomal dominant disorder including: Café-au-lait spot, skin fold freckling on flexural zones, and neurofibromas as well as tumours such as gliomas of optic nerve, gastrointestinal stromal tumours (GISTs), iris hamartomas and brain tumours. Duodenal somatostatinoma is associated with the syndrome which actually involves more often a duodenal tumour of GIST type than a somatostatin secreting neoplasia. Other neuroendocrine tumours are reported: Gastrointestinal NENs at the level of rectum or jejunum and pheocromocytoma. Overall, one quarter of subjects have gastrointestinal tumours of different types. Somatostatinoma, when not located on pancreas but in duodenoum, may be registered in subjects with neurofibromatosis type 1 most probably in addition to other tumours. Overall, this type of neuroendocrine tumour with a challenging presentation has a poor prognosis unless adequate radical surgery is promptly offered to the patient.

show abstract

5-Hydroxytriptamine and Skeleton Influence Clinical Study

Cited by 5 publications

References 0 publications

Clinical Data on Transitory Teriparatide-related Hypercalcemia in Daily Practice Treatment for Severe Menopausal Osteoporosis

Clinical Data on Transitory Teriparatide-related Hypercalcemia in Daily Practice Treatment for Severe Menopausal Osteoporosis

Anorexia nervosa: COVID‑19 pandemic period (Review)

Somatostatinoma: Beyond neurofibromatosis type 1 (Review)

Contact Info

Product

Resources

About